Top
Summary
All studies
Mortality
ICU
Hospitalization
Serious outcomes
Cases
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Analgesics⏵
Antiandrogens⏵
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Molnupiravir
Monoclonals⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins⏵
More⏵

Other
Feedback
Home
Top
All vitamin K studies
 
Feedback
Home
c19early.org COVID-19 treatment researchVitamin KVitamin K (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta
Home Adoption Other Treatments
@CovidAnalysis

Outcomes in COVID-19 vitamin K studies

Home
Post
Share
@CovidAnalysis
StudiesStudies
FeedbackFeedback
All studies   Mortality   ICU   Hospitalization   Serious outcomes   Cases   RCTs   RCT mortality   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies 14% 2 7,806 Improvement, Studies, Patients Relative Risk Mortality -200% 1 40 ICU admission -200% 1 40 Hospitalization 17% 1 40 Cases 14% 1 7,766 RCTs -200% 1 40 Prophylaxis 14% 1 7,766 Late -200% 1 40 Vitamin K for COVID-19 c19early.org November 2024 Favorsvitamin K Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ KOVIT Visser (DB RCT) -200% 3.00 [0.13-69.5] death 1/20 0/20 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.5 Late treatment -200% 3.00 [0.13-69.5] 1/20 0/20 200% higher risk Deschasaux-Tanguy 14% 0.86 [0.74-0.99] cases 7,766 (all patients) per SD change Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.04 Prophylaxis 14% 0.86 [0.74-0.99] 14% lower risk All studies 14% 0.86 [0.75-1.00] 1/20 0/20 14% lower risk 2 vitamin K COVID-19 studies c19early.org November 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.043 Effect extraction pre-specified(most serious outcome) Favors vitamin K Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ KOVIT Visser (DB RCT) -200% 3.00 [0.13-69.5] 1/20 0/20 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.5 Late treatment -200% 3.00 [0.13-69.5] 1/20 0/20 200% higher risk All studies -200% 3.00 [0.13-69.5] 1/20 0/20 200% higher risk 1 vitamin K COVID-19 mortality result c19early.org November 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.5 Favors vitamin K Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ KOVIT Visser (DB RCT) -200% 3.00 [0.34-26.5] 3/20 1/20 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.33 Late treatment -200% 3.00 [0.34-26.5] 3/20 1/20 200% higher risk All studies -200% 3.00 [0.34-26.5] 3/20 1/20 200% higher risk 1 vitamin K COVID-19 ICU result c19early.org November 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.33 Favors vitamin K Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ KOVIT Visser (DB RCT) 17% 0.83 [0.49-1.43] hosp. time 20 (n) 20 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.52 Late treatment 17% 0.83 [0.49-1.43] 20 (n) 20 (n) 17% lower risk All studies 17% 0.83 [0.49-1.43] 20 (n) 20 (n) 17% lower risk 1 vitamin K COVID-19 hospitalization result c19early.org November 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.52 Favors vitamin K Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ KOVIT Visser (DB RCT) -200% 3.00 [0.13-69.5] death 1/20 0/20 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.5 Late treatment -200% 3.00 [0.13-69.5] 1/20 0/20 200% higher risk All studies -200% 3.00 [0.13-69.5] 1/20 0/20 200% higher risk 1 vitamin K COVID-19 serious outcome c19early.org November 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.5 Effect extraction pre-specified(most serious outcome) Favors vitamin K Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Deschasaux-Tanguy 14% 0.86 [0.74-0.99] cases 7,766 (all patients) per SD change Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.04 Prophylaxis 14% 0.86 [0.74-0.99] 14% lower risk All studies 14% 0.86 [0.74-0.99] 14% lower risk 1 vitamin K COVID-19 case result c19early.org November 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.04 Favors vitamin K Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ KOVIT Visser (DB RCT) -200% 3.00 [0.13-69.5] death 1/20 0/20 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.5 Late treatment -200% 3.00 [0.13-69.5] 1/20 0/20 200% higher risk All studies -200% 3.00 [0.13-69.5] 1/20 0/20 200% higher risk 1 vitamin K COVID-19 Randomized Controlled Trials c19early.org November 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.5 Effect extraction pre-specified(most serious outcome) Favors vitamin K Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ KOVIT Visser (DB RCT) -200% 3.00 [0.13-69.5] 1/20 0/20 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.5 Late treatment -200% 3.00 [0.13-69.5] 1/20 0/20 200% higher risk All studies -200% 3.00 [0.13-69.5] 1/20 0/20 200% higher risk 1 vitamin K COVID-19 RCT mortality result c19early.org November 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.5 Favors vitamin K Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ KOVIT Visser (DB RCT) -200% 3.00 [0.13-69.5] death 1/20 0/20 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.5 Late treatment -200% 3.00 [0.13-69.5] 1/20 0/20 200% higher risk Deschasaux-Tanguy 14% 0.86 [0.74-0.99] cases 7,766 (all patients) per SD change Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.04 Prophylaxis 14% 0.86 [0.74-0.99] 14% lower risk All studies 14% 0.86 [0.75-1.00] 1/20 0/20 14% lower risk 2 vitamin K COVID-19 peer reviewed studies c19early.org November 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.043 Effect extraction pre-specified(most serious outcome) Favors vitamin K Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ KOVIT Visser (DB RCT) -200% 3.00 [0.13-69.5] death 1/20 0/20 Improvement, RR [CI] Treatment Control KOVIT Visser (DB RCT) -200% 3.00 [0.34-26.5] ICU 3/20 1/20 KOVIT Visser (DB RCT) 17% 0.83 [0.49-1.43] hosp. time 20 (n) 20 (n) Deschasaux-Tanguy 14% 0.86 [0.74-0.99] cases 7,766 (all patients) per SD change Vitamin K COVID-19 outcomes c19early.org November 2024 Favors vitamin K Favors control
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0